ICCC
NASDAQImmuCell Corporation
Price$9.86+3.66 (+59.03%)
2026-03-042026-06-05
News · 26 weeks43-100%
2025-12-142026-06-07
Mix3090d
- Insider15(50%)
- SEC Filings10(33%)
- Earnings4(13%)
- Leadership1(3%)
Latest news
25 items- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECSEC Form 10-Q filed by ImmuCell Corporation10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026. Management's Discussion: "Today we are reporting net income of $1.9 million for the first quarter of 2026, which is an increase of $0.5 million compared to the first quarter of 2025," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects
- SECAmendment: SEC Form 10-K/A filed by ImmuCell Corporation10-K/A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026. The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 22,
- SECSEC Form DEF 14A filed by ImmuCell CorporationDEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- INSIDERSEC Form 3 filed by new insider Dimarco Anthony3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Guillemette Gilles3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Turner Kathy V4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Tomsche David Scott4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Basse Gloria F4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Wainman Paul R4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECSEC Form PRE 14A filed by ImmuCell CorporationPRE 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- INSIDERSEC Form 4 filed by Gathagan Bryan K.4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Wainman Paul R4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Tomsche David Scott4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Brockmann Bobbi Jo4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Rosgen Steven T.4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Basse Gloria F4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECImmuCell Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsPORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors. Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsPORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: Domestic sales were $9.7 million in 2026, a 35.7% increase compared to 2025International sales were $0.6 million in 2026, a 30.2% decline compared to 2025Tri-Shield® sales
- INSIDERSEC Form 3 filed by new insider Turner Kathy V3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
ICCC FAQ
6 questionsWhat does ImmuCell Corporation do?
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and...Where does ICCC stock trade?
ImmuCell Corporation (ICCC) is listed on NASDAQ.What sector and industry is ICCC in?
ImmuCell Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did ImmuCell Corporation go public?
ImmuCell Corporation (ICCC) completed its IPO in 1987.What companies are similar to ICCC?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare ICCC side-by-side with any of them on Quantisnow.How can I track ICCC on Quantisnow?
Quantisnow aggregates ImmuCell Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICCC to receive live email and push alerts on every new disclosure.